Weaning and discontinuation of Epoprostenol in children with idiopathic, pulmonary arterial hypertension receiving concomitant bosentan

被引：60

作者：

Ivy, DD

Doran, A

Claussen, L

Bingaman, D

Yetman, A

机构：

[1] Univ Colorado, Childrens Hosp, Dept Pediat, Pediat Heart Lung Ctr,Pediat Pulm Hypertens Progr, Denver, CO 80218 USA

[2] NIH, Gen Clin Res Ctr Program, Natl Ctr Res Resources, Bethesda, MD USA

来源：

AMERICAN JOURNAL OF CARDIOLOGY | 2004年 / 93卷 / 07期

关键词：

D O I：

10.1016/j.amjcard.2003.12.031

中图分类号：

R5 [内科学];

学科分类号：

1002 [临床医学]; 100201 [内科学];

摘要：

In 7 of 8 children with idiopathic pulmonary arterial hypertension treated with intravenous epoprostenol for >1 year, concomitant use of bosentan allowed a reduction of epoprostenol and decreased its associated side effects without deterioration of clinical and hemodynamic parameters. In 3 children with normal or near-normal pulmonary artery pressure on epoprostenol, the addition of bosentan allowed discontinuation of epoprostenol and stabilization of hemodynamics for up to 1 year. (C) 2004 by Excerpta Medica, Inc.

引用

页码：943 / 946

页数：4

共 11 条

[1]

Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension [J].

Barst, RJ ;

Ivy, D ;

Dingemanse, J ;

Widlitz, A ;

Schmitt, K ;

Doran, A ;

Bingaman, D ;

Nguyen, N ;

Gaitonde, M ;

van Giersbergen, PLM .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 73 (04) :372-382

[2]

Vasodilator therapy for primary pulmonary hypertension in children [J].

Barst, RJ ;

Maislin, G ;

Fishman, AP .

CIRCULATION, 1999, 99 (09) :1197-1208

[3]

A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension [J].

Barst, RJ ;

Rubin, LJ ;

Long, WA ;

McGoon, MD ;

Rich, S ;

Badesch, DB ;

Groves, BM ;

Tapson, VF ;

Bourge, RC ;

Brundage, BH ;

Koerner, SK ;

Langleben, D ;

Keller, CA ;

Murali, S ;

Uretsky, BF ;

Clayton, LM ;

Jobsis, MM ;

Blackburn, SD ;

Shortino, D ;

Crow, JW .

NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (05) :296-301

[4]

EXPRESSION OF ENDOTHELIN-1 IN THE LUNGS OF PATIENTS WITH PULMONARY-HYPERTENSION [J].

GIAID, A ;

YANAGISAWA, M ;

LANGLEBEN, D ;

MICHEL, RP ;

LEVY, R ;

SHENNIB, H ;

KIMURA, S ;

MASAKI, T ;

DUGUID, WP ;

STEWART, DJ .

NEW ENGLAND JOURNAL OF MEDICINE, 1993, 328 (24) :1732-1739

[5]

Kim NH, 2003, CHEST, V124, P1612, DOI 10.1378/chest.124.4.1612

[6]

Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension [J].

McLaughlin, VV ;

Genthner, DE ;

Panella, MM ;

Rich, S .

NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (05) :273-277

[7]

Survival in primary pulmonary hypertension - The impact of epoprostenol therapy [J].

McLaughlin, VV ;

Shillington, A ;

Rich, S .

CIRCULATION, 2002, 106 (12) :1477-1482

[8]

Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension [J].

Rubens, C ;

Ewert, R ;

Halank, M ;

Wensel, R ;

Orzechowski, HD ;

Schultheiss, HP ;

Hoeffken, G .

CHEST, 2001, 120 (05) :1562-1569

[9]

Bosentan therapy for pulmonary arterial hypertension [J].

Rubin, LJ ;

Badesch, DB ;

Barst, RJ ;

Galiè, N ;

Black, CM ;

Keogh, A ;

Pulido, T ;

Frost, A ;

Roux, S ;

Leconte, I ;

Landzberg, M ;

Simonneau, G .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (12) :896-903

[10]

TREATMENT OF PRIMARY PULMONARY-HYPERTENSION WITH CONTINUOUS INTRAVENOUS PROSTACYCLIN (EPOPROSTENOL) - RESULTS OF A RANDOMIZED TRIAL [J].

RUBIN, LJ ;

MENDOZA, J ;

HOOD, M ;

MCGOON, M ;

BARST, R ;

WILLIAMS, WB ;

DIEHL, JH ;

CROW, J ;

LONG, W .

ANNALS OF INTERNAL MEDICINE, 1990, 112 (07) :485-491

← 1 2 →